|
1
|
Alagpulinsa DA, Kumar S, Talluri S,
Nanjappa P, Buon L, Chakraborty C, Samur MK, Szalat R, Shammas MA
and Munshi NC: Amplification and overexpression of E2 ubiquitin
conjugase UBE2T promotes homologous recombination in multiple
myeloma. Blood Adv. 3:3968–3972. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen F, Li M and Wang L: LncRNA CASC11
promotes hepatocellular carcinoma progression via upregulation of
UBE2T in a m(6)A-Dependent Manner. Front Oncol. 11:7726712021.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen Z, Jin P, Chen Z, Ye F, Ren Z, Ji T,
Li R and Yu L: The expression of circ_0090049 in hepatocellular
carcinoma and the molecular regulation mechanism of other
biological functions. Anticancer Drugs. 33:48–60. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dutta R, Guruvaiah P, Reddi KK, Bugide S,
Reddy Bandi DS, Edwards YJK, Singh K and Gupta R: UBE2T promotes
breast cancer tumor growth by suppressing DNA replication stress.
NAR Cancer. 4:zcac0352022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hao P, Kang B, Li Y, Hao W and Ma F: UBE2T
promotes proliferation and regulates PI3K/Akt signaling in renal
cell carcinoma. Mol Med Rep. 20:1212–1220. 2019.PubMed/NCBI
|
|
6
|
Hu W, Xiao L, Cao C, Hua S and Wu D: UBE2T
promotes nasopharyngeal carcinoma cell proliferation, invasion, and
metastasis by activating the AKT/GSK3β/β-catenin pathway.
Oncotarget. 7:15161–15172. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Huang W, Huang H, Xiao Y, Wang L, Zhang T,
Fang X and Xia X: UBE2T is upregulated, predicts poor prognosis,
and promotes cell proliferation and invasion by promoting
epithelial-mesenchymal transition via inhibiting autophagy in an
AKT/mTOR dependent manner in ovarian cancer. Cell Cycle.
21:780–791. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu LP, Yang M, Peng QZ, Li MY, Zhang YS,
Guo YH, Chen Y and Bao SY: UBE2T promotes hepatocellular carcinoma
cell growth via ubiquitination of p53. Biochem Biophys Res Commun.
493:20–27. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Luo C, Yao Y, Yu Z, Zhou H, Guo L, Zhang
J, Cao H, Zhang G and Li Yand Jiao Z: UBE2T knockdown inhibits
gastric cancer progression. Oncotarget. 8:32639–32654. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yin H, Wang X, Zhang X, Zeng Y, Xu Q, Wang
W, Zhou F and Zhou Y: UBE2T promotes radiation resistance in
non-small cell lung cancer via inducing epithelial-mesenchymal
transition and the ubiquitination-mediated FOXO1 degradation.
Cancer Lett. 494:121–131. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang W, Zhang Y, Yang Z, Liu X, Yang P,
Wang J, Hu K, He X, Zhang X and Jing H: High expression of UBE2T
predicts poor prognosis and survival in multiple myeloma. Cancer
Gene Ther. 26:347–355. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chang SC and Ding JL: Ubiquitination and
SUMOylation in the chronic inflammatory tumor microenvironment.
Biochim Biophys Acta Rev Cancer. 1870:165–175. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Damgaard RB: The ubiquitin system: From
cell signalling to disease biology and new therapeutic
opportunities. Cell Death Differ. 28:423–426. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Stewart MD, Ritterhoff T, Klevit RE and
Brzovic PS: E2 enzymes: More than just middle men. Cell Res.
26:423–440. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chang SC, Zhang BX and Ding JL: E2-E3
ubiquitin enzyme pairing-partnership in provoking or mitigating
cancers. Biochim Biophys Acta Rev Cancer. 1877:1886792022.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ye Y and Rape M: Building ubiquitin
chains: E2 enzymes at work. Nat Rev Mol Cell Biol. 10:755–764.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Deng L, Meng T, Chen L, Wei W and Wang P:
The role of ubiquitination in tumorigenesis and targeted drug
discovery. Signal Transduct Target Ther. 5:112020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu Y, Ji W, Yue N and Zhou W:
Ubiquitin-conjugating enzyme E2T promotes tumor stem cell
characteristics and migration of cervical cancer cells by
regulating the GRP78/FAK pathway. Open Life Sci. 16:1082–1090.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang X, Meng T, Cui S, Feng L, Liu D,
Pang Q and Wang P: Ubiquitination of nonhistone proteins in cancer
development and treatment. Front Oncol. 10:6212942020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tang H, Fang T, Ji M, Wang JP, Song LL,
Zhang QY and Wu JS: UBE2S exerts oncogenic activities in urinary
bladder cancer by ubiquitinating TSC1. Biochem Biophys Res Commun.
578:7–14. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhao B, Tsai YC, Jin B, Wang B, Wang Y,
Zhou H, Carpenter T, Weissman AM and Yin J: Protein engineering in
the ubiquitin system: Tools for discovery and beyond. Pharmacol
Rev. 72:380–413. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhao R, Yu Z, Mao X, Zheng Y, Wang Y and
Zhou Y: Knockout of UBE2S inhibits the proliferation of gastric
cancer cells and induces apoptosis by FAS-mediated death receptor
pathway. Exp Cell Res. 419:1132932022. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen Z, Zhang M, Lu Y, Ding T, Liu Z, Liu
Y, Zhou Z and Wang L: Overexpressed lncRNA FTX promotes the cell
viability, proliferation, migration and invasion of renal cell
carcinoma via FTX/miR4429/UBE2C axis. Oncol Rep. 48:1632022.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Huang GZ, Chen ZQ, Wu J, Shao TR, Zou C,
Ai YL and Lv XZ: Pan-Cancer analyses of the tumor microenvironment
reveal that ubiquitin-conjugating enzyme E2C Might Be a potential
immunotherapy target. J Immunol Res. 2021:92502072021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kariri Y, Toss MS, Alsaleem M, Elsharawy
KA, Joseph C, Mongan NP, Green AR and Rakha EA:
Ubiquitin-conjugating enzyme 2C (UBE2C) is a poor prognostic
biomarker in invasive breast cancer. Breast Cancer Res Treat.
192:529–539. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Presta I, Novellino F, Donato A, La Torre
D, Palleria C, Russo E, Malara N and Donato G: UbcH10 a major actor
in cancerogenesis and a potential tool for diagnosis and therapy.
Int J Mol Sci. 21:20412020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yang YF, Chang YC, Tsai KW, Hung MH and
Kang BH: UBE2C triggers HIF-1α-glycolytic flux in head and neck
squamous cell carcinoma. J Cell Mol Med. 26:3716–3725. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yuan Y, Xiao WW, Xie WH, Li RZ and Gao YH:
Prognostic value of ubiquitin E2 UBE2W and its correlation with
tumor-infiltrating immune cells in breast cancer. BMC Cancer.
21:4792021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zeng X, Zheng W, Sheng Y and Ma H: UBE2B
promotes ovarian cancer growth via promoting RAD18 mediated ZMYM2
monoubiquitination and stabilization. Bioengineered. 13:8000–8012.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang CY and Yang M: Functions of three
ubiquitin-conjugating enzyme 2 genes in hepatocellular carcinoma
diagnosis and prognosis. World J Hepatol. 14:956–971. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang M, Liu Y, Yin Y, Sun Z, Wang Y,
Zhang Z, Li F and Chen X: UBE2S promotes the development of ovarian
cancer by promoting PI3K/AKT/mTOR signaling pathway to regulate
cell cycle and apoptosis. Mol Med. 28:622022. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
van Wijk SJ and Timmers HT: The family of
ubiquitin-conjugating enzymes (E2s): Deciding between life and
death of proteins. FASEB J. 24:981–993. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Alpi AF, Chaugule V and Walden H:
Mechanism and disease association of E2-conjugating enzymes:
Lessons from UBE2T and UBE2L3. Biochem J. 473:3401–3419. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Alpi A, Langevin F, Mosedale G, Machida
YJ, Dutta A and Patel KJ: UBE2T, the Fanconi anemia core complex,
and FANCD2 are recruited independently to chromatin: A basis for
the regulation of FANCD2 monoubiquitination. Mol Cell Biol.
27:8421–8430. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hodson C, Cole AR, Lewis LP, Miles JA,
Purkiss A and Walden H: Structural analysis of human FANCL, the E3
ligase in the Fanconi anemia pathway. J Biol Chem. 286:32628–32637.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hodson C, Purkiss A, Miles JA and Walden
H: Structure of the human FANCL RING-Ube2T complex reveals
determinants of cognate E3-E2 selection. Structure. 22:337–344.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Rickman KA, Lach FP, Abhyankar A, Donovan
FX, Sanborn EM, Kennedy JA, Sougnez C, Gabriel SB, Elemento O,
Chandrasekharappa SC, et al: Deficiency of UBE2T, the E2 Ubiquitin
Ligase Necessary for FANCD2 and FANCI Ubiquitination, Causes FA-T
Subtype of Fanconi Anemia. Cell Rep. 12:35–41. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sheng Y, Hong JH, Doherty R, Srikumar T,
Shloush J, Avvakumov GV, Walker JR, Xue S, Neculai D, Wan JW, et
al: A human ubiquitin conjugating enzyme (E2)-HECT E3 ligase
structure-function screen. Mol Cell Proteomics. 11:329–341. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kar G, Keskin O, Nussinov R and Gursoy A:
Human proteome-scale structural modeling of E2-E3 interactions
exploiting interface motifs. J Proteome Res. 11:1196–1207. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Markson G, Kiel C, Hyde R, Brown S,
Charalabous P, Bremm A, Semple J, Woodsmith J, Duley S,
Salehi-Ashtiani K, et al: Analysis of the human E2 ubiquitin
conjugating enzyme protein interaction network. Genome Res.
19:1905–1911. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Pruneda JN, Littlefield PJ, Soss SE,
Nordquist KA, Chazin WJ, Brzovic PS and Klevit RE: Structure of an
E3:E2~Ub complex reveals an allosteric mechanism shared among
RING/U-box ligases. Mol Cell. 47:933–942. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lemonidis K, Arkinson C, Rennie ML and
Walden H: Mechanism, specificity, and function of FANCD2-FANCI
ubiquitination and deubiquitination. FEBS J. 289:4811–4829. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chaugule VK, Arkinson C, Rennie ML,
Kamarainen O, Toth R and Walden H: Allosteric mechanism for
site-specific ubiquitination of FANCD2. Nat Chem Biol. 16:291–301.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Cornwell MJ, Thomson GJ, Coates J,
Belotserkovskaya R, Waddell ID, Jackson SP and Galanty Y:
Small-Molecule Inhibition of UBE2T/FANCL-Mediated Ubiquitylation in
the Fanconi Anemia Pathway. ACS Chem Biol. 14:2148–2154.
2019.PubMed/NCBI
|
|
45
|
Frost MG, Mazloumi Aboukheili AM, Toth R
and Walden H: Characterization of FANCL variants observed in
patient cancer cells. Biosci Rep. 40:BSR201913042020. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yang Z, Wu XS, Wei Y, Polyanskaya SA, Iyer
SV, Jung M, Lach FP, Adelman ER, Klingbeil O, Milazzo JP, et al:
Transcriptional Silencing of ALDH2 confers a dependency on fanconi
anemia proteins in acute myeloid leukemia. Cancer Discov.
11:2300–2315. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Mehta PA and Ebens C: Fanconi Anemia.
GeneReviews((R)). Adam MP, Everman DB, Mirzaa GM, Pagon RA, Wallace
SE, Bean LJH, Gripp KW and Amemiya A: (Seattle, WA).
1993.PubMed/NCBI
|
|
48
|
Yang Y, Guo T, Liu R, Ke H, Xu W, Zhao S
and Qin Y: FANCL gene mutations in premature ovarian insufficiency.
Hum Mutat. 41:1033–1041. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Hira A, Yoshida K, Sato K, Okuno Y,
Shiraishi Y, Chiba K, Tanaka H, Miyano S, Shimamoto A, Tahara H, et
al: Mutations in the gene encoding the E2 conjugating enzyme UBE2T
cause Fanconi anemia. Am J Hum Genet. 96:1001–1007. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Virts EL, Jankowska A, Mackay C, Glaas MF,
Wiek C, Kelich SL, Lottmann N, Kennedy FM, Marchal C, Lehnert E, et
al: AluY-mediated germline deletion, duplication and somatic stem
cell reversion in UBE2T defines a new subtype of Fanconi anemia.
Hum Mol Genet. 24:5093–5108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Alpi AF, Pace PE, Babu MM and Patel KJ:
Mechanistic insight into site-restricted monoubiquitination of
FANCD2 by Ube2t, FANCL, and FANCI. Mol Cell. 32:767–777. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Ueki T, Park JH, Nishidate T, Kijima K,
Hirata K, Nakamura Y and Katagiri T: Ubiquitination and
downregulation of BRCA1 by ubiquitin-conjugating enzyme E2T
overexpression in human breast cancer cells. Cancer Res.
69:8752–8760. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Ozmen Yaylaci A and Canbek M: The role of
ubiquitin signaling pathway on liver regeneration in rats. Mol Cell
Biochem. 478:131–147. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Cabanas Morafraile E, Perez-Pena J,
Fuentes-Antras J, Manzano A, Pérez-Segura P, Pandiella A,
Galán-Moya EM and Ocaña A: Genomic Correlates of DNA damage in
breast cancer subtypes. Cancers (Basel). 13:21172021. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Tao Y, Li R, Shen C, Li J, Zhang Q, Ma Z,
Wang F and Wang Z: SENP1 is a crucial promotor for hepatocellular
carcinoma through deSUMOylation of UBE2T. Aging (Albany NY).
12:1563–1576. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Wei X, You X, Zhang J and Zhou C:
MicroRNA-1305 Inhibits the Stemness of LCSCs and tumorigenesis by
repressing the UBE2T-Dependent akt-signaling pathway. Mol Ther
Nucleic Acids. 16:721–732. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Zou R, Xu H, Li F, Wang S and Zhu L:
Increased Expression of UBE2T Predicting Poor survival of
epithelial ovarian cancer: Based on comprehensive analysis of
UBE2s, Clinical Samples, and the GEO Database. DNA Cell Biol.
40:36–60. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Zhu Z, Cao C, Zhang D, Zhang Z, Liu L, Wu
D and Sun J: UBE2T-mediated Akt ubiquitination and Akt/beta-catenin
activation promotes hepatocellular carcinoma development by
increasing pyrimidine metabolism. Cell Death Dis. 13:1542022.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Wang F, Zhong S, Mao C, Jin J and Wang H:
Circ_0000291 contributes to hepatocellular carcinoma tumorigenesis
by binding to miR-1322 to up-regulate UBE2T. Ann Hepatol.
27:1007222022. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Ren X, Li A, Ying E, Fang J, Li M and Yu
J: Upregulation of ubiquitin-conjugating enzyme E2T (UBE2T)
predicts poor prognosis and promotes hepatocellular carcinoma
progression. Bioengineered. 12:1530–1542. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Lioulia E, Mokos P, Panteris E and Dafou
D: UBE2T promotes β-catenin nuclear translocation in hepatocellular
carcinoma through MAPK/ERK-dependent activation. Mol Oncol.
16:1694–1713. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Ho NPY, Leung CON, Wong TL, Lau EYT, Lei
MML, Mok EHK, Leung HW, Tong M, Ng IOL, Yun JP, et al: The
interplay of UBE2T and Mule in regulating Wnt/β-catenin activation
to promote hepatocellular carcinoma progression. Cell Death Dis.
12:1482021. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Zhao X, Weng W, Jin M, Li S, Chen Q, Li B,
Zhou Z, Lan C and Yang Y: Identification of biomarkers based on
bioinformatics analysis: The expression of ubiquitin-conjugating
enzyme E2T (UBE2T) in the carcinogenesis and progression of
hepatocellular carcinoma. Med Sci Monit. 27:e9290232021.PubMed/NCBI
|
|
64
|
Sun J, Zhu Z, Li W, Shen M, Cao C, Sun Q,
Guo Z, Liu L and Wu D: UBE2T-regulated H2AX monoubiquitination
induces hepatocellular carcinoma radioresistance by facilitating
CHK1 activation. J Exp Clin Cancer Res. 39:2222020. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Guo J, Wang M, Wang JP and Wu CX:
Ubiquitin-conjugating enzyme E2T knockdown suppresses
hepatocellular tumorigenesis via inducing cell cycle arrest and
apoptosis. World J Gastroenterol. 25:6386–6403. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Liu LL, Zhu JM, Yu XN, Zhu HR, Shi X,
Bilegsaikhan E, Guo HY, Wu J and Shen XZ: UBE2T promotes
proliferation via G2/M checkpoint in hepatocellular carcinoma.
Cancer Manag Res. 11:8359–8370. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Yu H, Wang H, Dong W, Cao ZY, Li R, Yang
C, Cong WM, Dong H and Jin GZ: The diagnostic and prognostic value
of UBE2T in intrahepatic cholangiocarcinoma. PeerJ. 8:e84542020.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Zhu X, Li T, Niu X, Chen L and Ge C:
Identification of UBE2T as an independent prognostic biomarker for
gallbladder cancer. Oncol Lett. 20:442020. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Li L, Liu J and Huang W: E2F5 promotes
proliferation and invasion of gastric cancer through directly
upregulating UBE2T transcription. Dig Liver Dis. 54:937–945. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Lin X, Han T, Xia Q, Cui J, Zhuo M, Liang
Y, Su W, Wang L, Wang L, Liu Z and Xiao X: CHPF promotes gastric
cancer tumorigenesis through the activation of E2F1. Cell Death
Dis. 12:8762021. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Heitor da Silva Maues J, Ferreira Ribeiro
H, de Maria Maues Sacramento R, Maia de Sousa R, Pereira de Tommaso
R, Dourado Kovacs Machado Costa B, Cardoso Soares P, Pimentel
Assumpção P, de Fátima Aquino Moreira-Nunes C and Mário Rodriguez
Burbano R: Downregulated genes by silencing MYC pathway identified
with RNA-SEQ analysis as potential prognostic biomarkers in gastric
adenocarcinoma. Aging (Albany NY). 12:24651–24670. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Yu Z, Jiang X, Qin L, Deng H, Wang J, Ren
W, Li H, Zhao L, Liu H, Yan H, et al: A novel UBE2T inhibitor
suppresses Wnt/beta-catenin signaling hyperactivation and gastric
cancer progression by blocking RACK1 ubiquitination. Oncogene.
40:1027–1042. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Yu H, Xiang P, Pan Q, Huang Y, Xie N and
Zhu W: Ubiquitin-Conjugating Enzyme E2T is an independent
prognostic factor and promotes gastric cancer progression. Tumour
Biol. 37:11723–11732. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Luo M and Zhou Y: Comprehensive analysis
of differentially expressed genes reveals the promotive effects of
UBE2T on colorectal cancer cell proliferation. Oncol Lett.
22:7142021. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Wu M, Li X, Huang W, Chen Y, Wang B and
Liu X: Ubiquitin-conjugating enzyme E2T(UBE2T) promotes colorectal
cancer progression by facilitating ubiquitination and degradation
of p53. Clin Res Hepatol Gastroenterol. 45:1014932021. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Zheng YW, Gao PF, Ma MZ, Chen Y and Li CY:
Role of ubiquitin-conjugating enzyme E2T in the carcinogenesis and
progression of pancreatic cancer. Oncol Lett. 20:1462–1468. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Zhang J, Wang J, Wu J, Huang J, Lin Z and
Lin X: UBE2T regulates FANCI monoubiquitination to promote NSCLC
progression by activating EMT. Oncol Rep. 48:1392022. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Li Y, Yang X and Lu D: Knockdown of
ubiquitin-conjugating enzyme E2T (UBE2T) suppresses lung
adenocarcinoma progression via targeting fibulin-5 (FBLN5).
Bioengineered. 13:11867–11880. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Deng Y, Chen X, Huang C, Song J, Feng S,
Chen X and Zhou R: Screening and validation of significant genes
with poor prognosis in pathologic stage-I lung adenocarcinoma. J
Oncol. 2022:37940212022. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Chen Y, Jin L, Jiang Z, Liu S and Feng W:
Identifying and validating potential biomarkers of early stage lung
adenocarcinoma diagnosis and prognosis. Front Oncol. 11:6444262021.
View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Tu H, Wu M, Huang W and Wang L: Screening
of potential biomarkers and their predictive value in early stage
non-small cell lung cancer: A bioinformatics analysis. Transl Lung
Cancer Res. 8:797–807. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Wu ZH, Zhang YJ and Sun HY: High ubiquitin
conjugating enzyme E2 T mRNA expression and its prognostic
significance in lung adenocarcinoma: A study based on the TCGA
database. Medicine (Baltimore). 99:e185432020. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Yao R, Chen X, Wang L, Wang Y, Chi S, Li
N, Tian X, Li N and Liu J: Identification of key protein-coding
genes in lung adenocarcinomas based on bioinformatic analysis.
Transl Cancer Res. 8:2829–2840. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Perez-Pena J, Corrales-Sanchez V, Amir E,
Pandiella A and Ocana A: Ubiquitin-conjugating enzyme E2T (UBE2T)
and denticleless protein homolog (DTL) are linked to poor outcome
in breast and lung cancers. Sci Rep. 7:175302017. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Liu J and Liu X: UBE2T silencing inhibited
non-small cell lung cancer cell proliferation and invasion by
suppressing the wnt/β-catenin signaling pathway. Int J Clin Exp
Pathol. 10:9482–9488. 2017.PubMed/NCBI
|
|
86
|
Chen Y, Hong H, Wang Q, Li J, Zhang W,
Chen T and Li P: NEDD4L-induced ubiquitination mediating UBE2T
degradation inhibits progression of lung adenocarcinoma via
PI3K-AKT signaling. Cancer Cell Int. 21:6312021. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Zhu J, Ao H, Liu M, Cao K and Ma J: UBE2T
promotes autophagy via the p53/AMPK/mTOR signaling pathway in lung
adenocarcinoma. J Transl Med. 19:3742021. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Wang X, Liu Y, Leng X, Cao K, Sun W, Zhu J
and Ma J: UBE2T Contributes to the prognosis of esophageal squamous
cell carcinoma. Pathol Oncol Res. 27:6325312021. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Shen L, Zhao K, Li H, Ning B, Wang W, Liu
R, Zhang Y and Zhang A: Downregulation of UBE2T can enhance the
radiosensitivity of osteosarcoma in vitro and in vivo. Epigenomics.
11:1283–1305. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Wang Y, Leng H, Chen H, Wang L, Jiang N,
Huo X and Yu B: Knockdown of UBE2T inhibits osteosarcoma cell
proliferation, migration, and invasion by suppressing the PI3K/Akt
signaling pathway. Oncol Res. 24:361–369. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Cao W, Ni L, Li P, Wang QX, Li MM, Huang
SH and Dang NN: miR-498 Targets UBE2T to inhibit the proliferation
of malignant melanoma cells. Technol Cancer Res Treat.
21:153303382210824312022. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Gorlov I, Orlow I, Ringelberg C, Hernando
E, Ernstoff MS, Cheng C, Her S, Parker JS, Thompson CL,
Gerstenblith MR, et al: Identification of gene expression levels in
primary melanoma associated with clinically meaningful
characteristics. Melanoma Res. 28:380–389. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Lin CY, Yu CJ, Liu CY, Chao TC, Huang CC,
Tseng LM and Lai JI: CDK4/6 inhibitors downregulate the
ubiquitin-conjugating enzymes UBE2C/S/T involved in the
ubiquitin-proteasome pathway in ER + breast cancer. Clin Transl
Oncol. 24:2120–2135. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Xiao Y, Deng Z, Li Y, Wei B, Chen X, Zhao
Z, Xiu Y, Hu M, Alahdal M, Deng Z, et al: ANLN and UBE2T are
prognostic biomarkers associated with immune regulation in breast
cancer: A bioinformatics analysis. Cancer Cell Int. 22:1932022.
View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Li L and Li Q: miR-543 impairs breast
cancer cell phenotypes by targeting and suppressing
ubiquitin-conjugating enzyme E2T (UBE2T). Bioengineered.
12:12394–12406. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Fuentes-Antras J, Alcaraz-Sanabria AL,
Morafraile EC, Noblejas-López MDM, Galán-Moya EM, Baliu-Pique M,
López-Cade I, García-Barberán V, Pérez-Segura P, Manzano A, et al:
Mapping of genomic vulnerabilities in the post-translational
ubiquitination, SUMOylation and neddylation machinery in breast
cancer. Cancers (Basel). 13:8332021. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Qiao L, Dong C and Ma B: UBE2T promotes
proliferation, invasion and glycolysis of breast cancer cells by
regualting the PI3K/AKT signaling pathway. J Recept Signal
Transduct Res. 42:151–159. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Wang Y, Li Y, Liu B and Song A:
Identifying breast cancer subtypes associated modules and
biomarkers by integrated bioinformatics analysis. Biosci Rep.
41:BSR202032002021. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Wen M, Kwon Y, Wang Y, Mao JH and Wei G:
Elevated expression of UBE2T exhibits oncogenic properties in human
prostate cancer. Oncotarget. 6:25226–25239. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Wen C, Ge Q, Dai B, Li J, Yang F, Meng J,
Gao S, Fan S and Zhang L: Signature for prostate cancer based on
autophagy-related genes and a nomogram for quantitative risk
stratification. Dis Markers. 2022:75989422022. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Gong YQ, Peng D, Ning XH, Yang XY, Li XS,
Zhou LQ and Guo YL: UBE2T silencing suppresses proliferation and
induces cell cycle arrest and apoptosis in bladder cancer cells.
Oncol Lett. 12:4485–4492. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Cai H, Chen H, Huang Q, Zhu JM, Ke ZB, Lin
YZ, Zheng QS, Wei Y, Xu N and Xue XY: Ubiquitination-Related
molecular subtypes and a novel prognostic index for bladder cancer
patients. Pathol Oncol Res. 27:16099412021. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Wu Y, Zhang C, Peng D, He S, Huang C, Qian
J, Zhu W, Feng N, Gong Y, Li X and Zhou L: MiR-182-5p inhibits the
tumorigenesis of clear cell renal cell carcinoma by repressing
UBE2T. Hum Cell. 35:542–556. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Gao J, Ye F, Han F, Wang X, Jiang H and
Zhang J: A novel radiogenomics biomarker based on hypoxic-gene
subset: Accurate survival and prognostic prediction of renal clear
cell carcinoma. Front Oncol. 11:7398152021. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Li C, Wendlandt EB, Darbro B, Xu H, Thomas
GS, Tricot G, Chen F, Shaughnessy JD Jr and Zhan F: Genetic
analysis of multiple myeloma identifies cytogenetic alterations
implicated in disease complexity and progression. Cancers (Basel).
13:5172021. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Derenzini E, Mondello P, Erazo T,
Portelinha A, Liu Y, Scallion M, Asgari Z, Philip J, Hilden P,
Valli D, et al: BET Inhibition-Induced GSK3β feedback enhances
lymphoma vulnerability to PI3K Inhibitors. Cell Rep. 24:2155–2166.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Wang Z, Chen N, Liu C, Cao G, Ji Y, Yang W
and Jiang Q: UBE2T is a prognostic biomarker and correlated with
Th2 cell infiltrates in retinoblastoma. Biochem Biophys Res Commun.
614:138–144. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Huang P, Guo Y, Zhao Z, Ning W, Wang H, Gu
C, Zhang M, Qu Y, Zhang H and Song Y: UBE2T promotes glioblastoma
invasion and migration via stabilizing GRP78 and regulating EMT.
Aging (Albany NY). 12:10275–10289. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Wang L, Tang L, Xu R, Ma J, Tian K, Liu Y,
Lu Y, Wu Z and Zhu X: DEPDC1B regulates the progression of human
chordoma through UBE2T-mediated ubiquitination of BIRC5. Cell Death
Dis. 12:7532021. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Liu F, Zhu C, Gao P, Zheng S and Li C:
Ubiquitin-conjugating enzyme E2T regulates cell proliferation and
migration in cholangiocarcinoma. Anticancer Drugs. 31:836–846.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Wang L, Zhang Z and Tian H:
Hsa_circ_0092887 targeting miR-490-5p/UBE2T promotes paclitaxel
resistance in non-small cell lung cancer. J Clin Lab Anal.
37:e247812023. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Ramaekers CH, van den Beucken T, Meng A,
Kassam S, Thoms J, Bristow RG and Wouters BG: Hypoxia disrupts the
Fanconi anemia pathway and sensitizes cells to chemotherapy through
regulation of UBE2T. Radiother Oncol. 101:190–197. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Xu MD, Liu SL, Zheng BB, Wu J, Wu MY,
Zhang Y, Gong FR, Tao M, Zhang J and Li W: The
radiotherapy-sensitization effect of cantharidin: Mechanisms
involving cell cycle regulation, enhanced DNA damage, and inhibited
DNA damage repair. Pancreatology. 18:822–832. 2018. View Article : Google Scholar : PubMed/NCBI
|
